

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 27 Source of Registration (SR) information in REGISTRY updated
and searchable
NEWS 4 JAN 27 A new search aid, the Company Name Thesaurus, available in
CA/CAPLUS
NEWS 5 FEB 05 German (DE) application and patent publication number format
changes
NEWS 6 MAR 03 MEDLINE and L MEDLINE reloaded
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 03 FRANCEPAT now available on STN
NEWS 9 MAR 29 Pharmaceutical Substances (PS) now available on STN
NEWS 10 MAR 29 WPIFV now available on STN
NEWS 11 MAR 29 New monthly current-awareness alert (SDI) frequency in RAPRA
NEWS 12 APR 26 PROMT: New display field available
NEWS 13 APR 26 IFIPAT/IFIUDB/IFICDB: New super search and display field
available
NEWS 14 APR 26 LITAlert now available on STN
NEWS 15 APR 27 NLDB: New search and display fields available
NEWS 16 May 10 PROUSDDR now available on STN
NEWS 17 May 19 PROUSDDR: One FREE connect hour, per account, in both May
and June 2004
NEWS 18 May 12 EXTEND option available in structure searching
NEWS 19 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 20 May 17 FRFULL now available on STN

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:49:35 ON 21 MAY 2004

=> file medline, uspatful, dgene, embase, biosis, wpids, japio, biobusiness,
scisearch, hcaplus, jicst, fsta
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 14:50:28 ON 21 MAY 2004

FILE 'USPATFULL' ENTERED AT 14:50:28 ON 21 MAY 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'WPIDS' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 Japanese Patent Office (JPO) - JAPIO

FILE 'BIOBUSINESS' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'SCISEARCH' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'HCAPLUS' ENTERED AT 14:50:28 ON 21 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JICST-EPLUS' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'FSTA' ENTERED AT 14:50:28 ON 21 MAY 2004
COPYRIGHT (C) 2004 International Food Information Service

=> s factor VIII adj von willibrand factor
L1 0 FACTOR VIII ADJ VON WILLIBRAND FACTOR

=> s factor VIII-von Willebrand factor complex
L2 202 FACTOR VIII-VON WILLEBRAND FACTOR COMPLEX

=> s l2 and purification
L3 44 L2 AND PURIFICATION

=> s l3 and (no low molecular weight vWF multimers
UNMATCHED LEFT PARENTHESIS 'AND (NO'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l3 not (low molecular weight vWF multimer)
L4 44 L3 NOT (LOW MOLECULAR WEIGHT VWF MULTIMER)

=> s l4 and high molecular weight vWF multimer
L5 0 L4 AND HIGH MOLECULAR WEIGHT VWF MULTIMER

=> d l4 ti abs ibib tot

L4 ANSWER 1 OF 44 MEDLINE on STN

TI The factor VIII/von Willebrand factor complex: basic and clinical issues.

AB Factor VIII (FVIII) and von Willebrand factor (VWF) are two distinct but related glycoproteins that circulate in plasma as a tightly bound complex (FVIII/VWF). Their deficiencies or structural defects are responsible for the most common inherited bleeding disorders, namely hemophilia A (HA) and von Willebrand's disease (VWD). The VWF has a dual role in hemostasis: first it promotes platelet adhesion to thrombogenic surfaces as well as platelet-to-platelet cohesion during thrombus formation; second, it is the carrier for FVIII in plasma. FVIII acts as a co-factor to accelerate the activation of factor X by activated factor IX in the coagulation cascade. After many years of investigations, the molecular mechanisms of FVIII/VWF interactions are now well known and recent biochemical investigations have confirmed that VWF is a key partner for FVIII, playing significant roles in FVIII function, its production and its stabilization, in its conformation and immunogenicity. FVIII and VWF are both present in most plasma-derived FVIII/VWF concentrates used in clinical practice. FVIII/VWF concentrates can be classified into three main categories according to the degree of their purification. Intermediate-high purity plasma-derived concentrates containing FVIII/VWF currently in use since 1987 carry a low risk of transmitting blood-borne infections. Concentrate safety depends on the interaction of two factors: the decrease of viral plasma load and the increase of viral inactivation. These FVIII/VWF concentrates are currently used in type 3 VWD and in type 1 or 2 VWD patients who are unresponsive to desmopressin (DDAVP). More recently the presence of the physiologic FVIII/VWF complex has been considered to play an important role also in replacement therapy for patients with HA. The correct use of FVIII/VWF concentrates in VWD and HA have been reported in several national and international guidelines.

2003, Ferrata Storti Foundation

ACCESSION NUMBER: 2003299060 MEDLINE

DOCUMENT NUMBER: PubMed ID: 12826528

TITLE: The factor VIII/von Willebrand factor complex: basic and clinical issues.

AUTHOR: Federici Augusto B

CORPORATE SOURCE: Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Internal Medicine, IRCCS Maggiore Hospital and University of Milan, Italy.. augusto.federici@unimi.it

SOURCE: Haematologica, (2003 Jun) 88 (6) EREP02. Ref: 40
Journal code: 0417435. ISSN: 1592-8721.

PUB. COUNTRY: Italy

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200401

ENTRY DATE: Entered STN: 20030627
Last Updated on STN: 20040130
Entered Medline: 20040129

L4 ANSWER 2 OF 44 MEDLINE on STN

TI Isolation of the factor VIII-von Willebrand factor complex directly from plasma by gel filtration.

AB A high capacity gel filtration system was developed with the purpose of isolating factor VIII (FVIII) and von Willebrand factor (vWF) directly from plasma in significantly higher yields than obtained by cryoprecipitation, the technique most commonly used to recover FVIII-vWF from human plasma. After laboratory-scale gel filtration of plasma, a FVIII-containing fraction was collected containing about 90% of FVIII in

the applied plasma and with almost tenfold higher purity than that obtained by cryoprecipitation. The gel filtration step has been scaled up for use as the initial step in the manufacturing process for a FVIII preparation (Nordiate).

ACCESSION NUMBER: 1999007008 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9792522
TITLE: Isolation of the **factor VIII-von Willebrand factor complex** directly from plasma by gel filtration.
AUTHOR: Kaersgaard P; Barington K A
CORPORATE SOURCE: HemaSure Denmark A/S, Gentofte.
SOURCE: Journal of chromatography. B, Biomedical sciences and applications, (1998 Sep 18) 715 (2) 357-67.
Journal code: 9714109. ISSN: 1387-2273.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199812
ENTRY DATE: Entered STN: 19990115
Last Updated on STN: 19990115
Entered Medline: 19981218

L4 ANSWER 3 OF 44 MEDLINE on STN
TI Application of a new statistical approach to optimize the immunopurification of antihemophilia A factor.
AB Our aim was to optimize the immunopurification process of human factor VIII. This **purification** was performed using a mouse monoclonal anti-factor VIII light-chain antibody. Previous dissociation of the **factor VIII-von Willebrand factor complex** with CaCl₂ led to a 50% increase of the factor VIII adsorption on the immunosorbent. The optimization of the elution step required the analysis of the effects of two parameters, pH and ionic strength, on four different responses: elution yield, concentration, specific activity and stability of factor VIII. For this purpose, a multifunctional method using Doehlert matrices for statistically designed experiments was applied. This methodology allowed us to obtain, with only seven experiments, a 60% increase of the elution yield and a two-fold increase of the specific activity of factor VIII.

ACCESSION NUMBER: 93203403 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8454702
TITLE: Application of a new statistical approach to optimize the immunopurification of antihemophilia A factor.
AUTHOR: Bihoreau N; Layet S; Fontaine-Aupart M P; Paolantonacci P
CORPORATE SOURCE: T.M. Innovation (Centre National de Transfusion Sanguine-Institut Merieux, Les Ulis, France.
SOURCE: Journal of chromatography, (1993 Jan 29) 612 (1) 49-56.
Journal code: 0427043. ISSN: 0021-9673.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199304
ENTRY DATE: Entered STN: 19930507
Last Updated on STN: 19970203
Entered Medline: 19930422

L4 ANSWER 4 OF 44 MEDLINE on STN
TI The interaction of the **factor VIII/von Willebrand factor complex** (VIII/vWf), with guanidinium-derivatized matrices.
AB Five different guanidinium (Gu)-derivatized agarose matrices were investigated for their potential in chromatographically resolving the Factor VIII/von Willebrand complex, VIII/vWf, fibrinogen, Fg, and

bad date

fibronectin, Fn, from cryoprecipitate. Using conventional NaCl gradient methodology it was found that the order of elution of specific plasma proteins, and the yield of VIII/vWf, varied with the methods used to derivatize the agarose beads. Good yields of VIII:C (generally 30-45%) were obtained with Gu-matrices prepared by bis-oxirane coupling procedures. Cryoprecipitate binding studies showed that the capacity of Gu-Sepharose 4B, prepared by isourea modification of amino-Sepharose 4B, was 36 units VIII/vWf per ml matrix. The product, depleted of both Fg and Fn, had a specific activity of 2 units VIII:C per mg total protein, (yield 100% vWf:Ag and 47% VIII:C).

ACCESSION NUMBER: 92240106 MEDLINE
DOCUMENT NUMBER: PubMed ID: 1368084
TITLE: The interaction of the **factor VIII/von Willebrand factor complex** (VIII/vWf), with guanidinium-derivatized matrices.
AUTHOR: Saundry R H; Savidge G F
CORPORATE SOURCE: Coagulation Research Laboratory, Rayne Institute, St. Thomas' Hospital, London, UK.
SOURCE: Bioseparation, (1991) 2 (3) 177-86.
Journal code: 9011423. ISSN: 0923-179X.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Biotechnology
ENTRY MONTH: 199206
ENTRY DATE: Entered STN: 19950809
Last Updated on STN: 19980206
Entered Medline: 19920602

L4 ANSWER 5 OF 44 MEDLINE on STN
TI Topography of the human **factor VIII-von Willebrand factor complex**.

AB Factor VIII circulates in noncovalent complex with von Willebrand factor (vWf). The topography of this complex was evaluated by fluorescence energy transfer using factor VIII subunits modified with N-(1-pyrenyl)maleimide (NPM; fluorescence donor) and vWf-derived fragments modified with 7-diethylamino-3-[4'-maleimidylphenyl]-4-methyl coumarin (CPM; fluorescence acceptor). Results from a previous study indicated an interfactor VIII subunit distance of 20 A separating Cys528 and Cys1858 in the factor VIII heavy and light chains, respectively (Fay, P.J., and Smudzin, T. M. (1989) J. Biol. Chemical 264, 14005-14010). Fluorophore modification of the vWf SPIII homodimer (residues 1-1365) indicated multiple attachment sites at Cys126/135/1360 as determined from sequence analysis of fluorescent tryptic peptides derived from the modified protein. Based upon donor quenching data, an interfluorophore distance of approximately 28 A was calculated separating NPM-factor VIII light chain or factor VIII reconstituted from NPM-light chain plus unmodified heavy chain, from CPM-SPIII. A similar value (29 A) was obtained for NPM-light chain paired with CPM-SPIII-T4 (vWf residues 1-272), suggesting that donor quenching resulted primarily from modified residue(s) Cys126/135 in the acceptor. No energy transfer was observed for the NPM-heavy chain/CPM-SPIII pairing. However, when NPM-heavy chain was reassociated with unmodified light chain prior to reaction with CPM-SPIII or CPM-SPIII-T4, energy transfer was observed with calculated interfluorophore distances of approximately 31 and 34 A, respectively. Levels of acceptor resulting in maximal donor quenching suggested an equimolar stoichiometry of factor VIII (light chain)/vWf fragment in the reconstituted complexes. These results indicate a close spatial arrangement among the A3 domain of factor VIII light chain, the A2 domain of factor VIII heavy chain, and the NH2 terminus region of vWf in the factor VIII-vWf complex.

ACCESSION NUMBER: 90202891 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2108154

TITLE: Topography of the human **factor VIII-von Willebrand factor complex**.
AUTHOR: Fay P J; Smudzin T M
CORPORATE SOURCE: Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642.
CONTRACT NUMBER: HL-38199 (NHLBI)
SOURCE: Journal of biological chemistry, (1990 Apr 15) 265 (11) 6197-202.
Journal code: 2985121R. ISSN: 0021-9258.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199005
ENTRY DATE: Entered STN: 19900601
Last Updated on STN: 19900601
Entered Medline: 19900510

L4 ANSWER 6 OF 44 MEDLINE on STN

TI Differential proteolytic activation of **factor VIII-von Willebrand factor complex** by thrombin.

AB Blood coagulation factor VIII (fVIII) is a plasma protein that is decreased or absent in hemophilia A. It is isolated as a mixture of heterodimers that contain a variably sized heavy chain and a common light chain. Thrombin catalyzes the activation of fVIII in a reaction that is associated with cleavages in both types of chain. We isolated a serine protease from Bothrops jararacussu snake venom that catalyzes thrombin-like heavy-chain cleavage but not light-chain cleavage in porcine fVIII as judged by NaDodSO₄/PAGE and N-terminal sequence analysis. Using a plasma-free assay of the ability of activated fVIII to function as a cofactor in the activation of factor X by factor IXa, we found that fVIII is activated by the venom enzyme. The venom enzyme-activated fVIII was isolated in stable form by cation-exchange HPLC. von Willebrand factor inhibited venom enzyme-activated fVIII but not thrombin-activated fVIII. These results suggest that the binding of fVIII to von Willebrand factor depends on the presence of an intact light chain and that activated fVIII must dissociate from von Willebrand factor to exert its cofactor effect. Thus, proteolytic activation of fVIII-von Willebrand factor complex appears to be differentially regulated by light-chain cleavage to dissociate the complex and heavy-chain cleavage to activate the cofactor function.

ACCESSION NUMBER: 89367278 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2505252
TITLE: Differential proteolytic activation of **factor VIII-von Willebrand factor complex** by thrombin.
AUTHOR: Hill-Eubanks D C; Parker C G; Lollar P
CORPORATE SOURCE: Department of Biochemistry, University of Vermont, Burlington 05405.
CONTRACT NUMBER: HL-35058 (NHLBI)
HL-40921 (NHLBI)
SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (1989 Sep) 86 (17) 6508-12.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198910
ENTRY DATE: Entered STN: 19900309
Last Updated on STN: 19970203
Entered Medline: 19891006

L4 ANSWER 7 OF 44 MEDLINE on STN

TI Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.

AB The known transmission of viral diseases, particularly AIDS (HIV, LAV, HTLV-III), has led to the mandatory use of virus-inactivated coagulation factor concentrates for treatment of bleeding disorders due to deficient or abnormal synthesis of the factor VIII/von Willebrand factor complex. The present investigation was undertaken to study the influence of heat-treatment on the von Willebrand factor (vWf). Using normal plasma as reference material, we studied the influence of low-purification steps in a simple cryo-plasma and a unrefined freeze-dried cryoprecipitate. For comparison, non-heated and heat-inactivated concentrates of different manufacture representing varying heat-treatment protocols were studied using quantitation of von Willebrand factor antigen (vWf:Ag) by electroimmunoassay and ELISA, and investigation of vWf multimeric composition. A locally produced factor VIII concentrate was studied before and after exposure to 68 degrees C for 72 hours (dry state). Whenever possible, commercial preparations manufactured prior to the heat-treatment era were compared with the present product. The locally produced high purity concentrate elicited only minor changes in oligomeric satellite pattern, which did not change after dry heat exposure. In principle, no major differences were found between non-heated and pasteurized commercial concentrates of same manufactural origin.

ACCESSION NUMBER: 88018700 MEDLINE

DOCUMENT NUMBER: PubMed ID: 3116714

TITLE: Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.

AUTHOR: Ingerslev J; Bukh A; Wallevik K; Moller N P; Stenbjerg S

CORPORATE SOURCE: Department of Clinical Immunology, University Hospital Aarhus, Denmark.

SOURCE: Thrombosis research, (1987 Jul 15) 47 (2) 175-82.
Journal code: 0326377. ISSN: 0049-3848.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals; AIDS

ENTRY MONTH: 198710

ENTRY DATE: Entered STN: 19900305

Last Updated on STN: 19900305

Entered Medline: 19871028

L4 ANSWER 8 OF 44 MEDLINE on STN

TI Investigation of a coagulation accelerating factor (CAF) in glomerulonephritis.

AB A coagulation accelerating factor was purified from the plasma of two patients with glomerulonephritis (GN) who suffered from thrombotic complications. The factor co-purified with factor VIII /von Willebrand factor complex (FVIII/vWf) and under dissociating conditions remained associated with the factor VIII coagulant activity (FVIII). Control purified FVIII/vWf showed no coagulation accelerating activity under the experimental conditions used. The levels of coagulation accelerating factor, FVIII and von Willebrand factor (vWf) were reduced by incubation with rabbit anti-human FVIII/vWf or human anti-FVIII serum indicating a close association of these three activities. Multimeric analysis of the plasma FVIII/vWf complex from the two patients demonstrated a reduction in the high molecular weight multimers and the presence of an additional band not present on analysis of normal FVIII/vWf. It is suggested that the coagulation accelerating factor represents an active form of FVIII which has different in vitro properties to thrombin activated FVIII.

ACCESSION NUMBER: 85122559 MEDLINE

DOCUMENT NUMBER: PubMed ID: 3918561
TITLE: Investigation of a coagulation accelerating factor (CAF) in glomerulonephritis.
AUTHOR: Salem H H; Howard M A; Koutts J; Firkin B G
SOURCE: British journal of haematology, (1985 Mar) 59 (3) 485-96.
Journal code: 0372544. ISSN: 0007-1048.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198504
ENTRY DATE: Entered STN: 19900320
Last Updated on STN: 19900320
Entered Medline: 19850423

L4 ANSWER 9 OF 44 USPATFULL on STN

TI Method for producing a **factor VIII/von Willebrand factor complex**

AB The invention relates to a method for the production of factor VIII:C/von Willebrand factor complex from plasma or a plasma fraction by chromatography in a cation exchanger, wherein the factor VIII:C/von Willebrand factor complex is obtained with at least 300 times the purity of the plasma and the yield of factor VIII:C and the von Willebrand factor is at least 50% in relation to cryoprecipitates or analogous plasma fractions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:215997 USPATFULL
TITLE: Method for producing a **factor VIII/von Willebrand factor complex**

INVENTOR(S): Linnau, Yendra, Vienna, AUSTRIA
Schoenhofer, Wolfgang, St. Poelten, AUSTRIA

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, AUSTRIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6605222	B1	20030812
	WO 9943712		19990902
APPLICATION INFO.:	US 2001-623245		20010319 (9)
	WO 1999-AT48		19990225

bad date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1998-866	19980520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Therkorn, Ernest G.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP, Fedrick, Michael F.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	203	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 44 USPATFULL on STN

TI Controllable ion-exchange membranes

AB Multilayered porous materials are formed by coating a porous substrate with a metal and adsorbing an organic layer comprising a recognition moiety onto the metal film. The recognition moiety interacts with an analyte of interest allowing for its detection, **purification**, etc. Suitable recognition moieties can be selected from a range of

species including, small molecules, polymers and biomolecules and the like. The novel porous materials of the invention can be utilized in an array of methods including, ion-exchange, ion-selective ion-exchange, assays, affinity dialysis, size exclusion dialysis and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:275837 USPATFULL
TITLE: Controllable ion-exchange membranes
INVENTOR(S): Hou, Zhizhong, Davis, CA, United States
Stroeve, Pieter, Davis, CA, United States
Abbott, Nicholas, Madison, WI, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6468657	B1	20021022
APPLICATION INFO.:	US 1998-206084		19981204 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Le, Hoa T.		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	71		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	3454		

6307032

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 11 OF 44 USPATFULL on STN
TI Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
AB There is disclosed a vWF derivative comprised of vWF, immobilized on a carrier, which is characterized in that the vWF is r-vWF, as well as a method of isolating proteins which bind to vWF, by using this vWF derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:32215 USPATFULL
TITLE: Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
INVENTOR(S): Schwarz, Hans-Peter, Vienna, AUSTRIA
Turecek, Peter, Klosterneuburg, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019036	A1	20020214
APPLICATION INFO.:	US 2001-967937	A1	20011002 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-319116, filed on 2 Jun 1999, PENDING A 371 of International Ser. No. WO 1997-AT253, filed on 19 Nov 1997, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-2178	19961213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HELLER EHRMAN WHITE & MCAULIFFE LLP, 1666 K STREET,NW, SUITE 300, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	598	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 44 USPATFULL on STN

TI Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

AB Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occurring Factor VIII. The polypeptides find use in treatment of Hemophilia A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:29368 USPATFULL

TITLE: Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

INVENTOR(S): Van Ooyen, Albert Johannes Joseph, Voorburg,
NETHERLANDS
Pannekoek, Hans, Aalsmeer, NETHERLANDS

Verbeet, Martinus Philippus, Amsterdam, NETHERLANDS

Van Leen, Robert Willem, Nijmegen, NETHERLANDS

PATENT ASSIGNEE(S): Baxter Trading GmbH, Vienna, AUSTRIA (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6346513	B1	20020212
APPLICATION INFO.:	US 1995-416535		19950403 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-272947, filed on 11 Jul 1994, now abandoned Continuation of Ser. No. US 1992-879328, filed on 7 May 1992, now abandoned Continuation of Ser. No. US 1998-205226, filed on 10 Jun 1998, now patented, Pat. No. US 5171844		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1987-U2011218	19870612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S.F.	
ASSISTANT EXAMINER:	Schnizer, Holly	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1130	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 44 USPATFULL on STN

TI Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

AB Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occurring Factor VIII. The polypeptides find use in treatment of Hemophilia A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:202415 USPATFULL

TITLE: Proteins with Factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them

INVENTOR(S): Van Ooyen, Albert Johannes Joseph, Voorburg,

Netherlands
Pannekoek, Hans, Aalsmeer, Netherlands
Verbeet, Martinus Philippus, Amsterdam, Netherlands
Van Leen, Robert Willem, Nijmegen, Netherlands
PATENT ASSIGNEE(S): Baxter Trading GmbH, Vienna, Australia (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316226	B1	20011113
APPLICATION INFO.:	US 1995-416532		19950403 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-272952, filed on 11 Jul 1994, now abandoned Continuation of Ser. No. US 1992-990895, filed on 15 Dec 1992, now abandoned Division of Ser. No. US 1988-205226, filed on 10 Jun 1988, now patented, Pat. No. US 5171844		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1987-201121	19870612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Low, Christopher S. F.	
ASSISTANT EXAMINER:	Schnizer, Holly	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 12 Drawing Page(s)	
LINE COUNT:	1176	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 14 OF 44 USPATFULL on STN
TI Support for high performance affinity chromatography and other uses
AB Multilayered particulate materials are formed by coating a particulate
substrate with a metal and adsorbing an organic layer comprising a
recognition moiety onto the metal film. The recognition moiety interacts
with an analyte of interest allowing for its detection,
purification, etc. Suitable recognition moieties can be selected
from a range of species including, small molecules, polymers and
biomolecules and the like. The novel particulate materials of the
invention can be utilized in an array of methods including,
ion-exchange, ion-selective ion-exchange, assays, affinity dialysis,
size exclusion dialysis, as supports in solid phase synthesis,
combinatorial synthesis and screening of compound libraries and the
like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:136295 USPATFULL
TITLE: Support for high performance affinity chromatography
and other uses
INVENTOR(S): Abbott, Nicholas, Madison, WI, United States
Stroeve, Pieter, Davis, CA, United States
Dubrovsky, Timothy B., Flemington, NJ, United States
Hou, Zhizhong, Davis, CA, United States
PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6277489	B1	20010821
APPLICATION INFO.:	US 1998-205750		19981204 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Le, Hoa T.		

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 3868
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 15 OF 44 USPATFULL on STN

TI Stable factor VIII/von Willebrand
factor complex

AB There are disclosed a stable factor VIII/vWF-complex, particularly
comprising high-molecular vWF multimers, being free from low-molecular
vWF molecules and from proteolytic vWF degradation products, as well as
a method of producing this complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:67424 USPATFULL

TITLE: Stable factor VIII/von
Willebrand factor complex

INVENTOR(S): Fischer, Bernhard, Vienna, Austria
Mitterer, Artur, Mannsdorf, Austria
Dorner, Friedrich, Vienna, Austria
Eibl, Johann, Vienna, Austria

PATENT ASSIGNEE(S): Baxter Aktiengesellschaft, Vienna, Austria (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6228613	B1	20010508
	WO 9734930		19970925
APPLICATION INFO.:	US 1998-142768		19981106 (9)
	WO 1997-AT55		19970313
			19981106 PCT 371 date
			19981106 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1996-494	19960315
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Robinson, Hope A.	
LEGAL REPRESENTATIVE:	Heller Ehrman White & McAuliffe	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	1098	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 16 OF 44 USPATFULL on STN

TI Fibrinogen concentrate obtained from blood plasma, process and plant for
its preparation

AB A fibrinogen concentrate has a purity of 98% or higher and is free of
viral contaminants and proteases. The fibrinogen concentrate is obtained
by subjecting a solubilized plasma fraction containing fibrinogen to a
viral inactivation chemical treatment using a solvent/detergent,
subjecting the resulting viral-inactivated fraction to precipitation in
a solution containing an amino acid at an acidic pH to obtain a
supernatant, filtering the supernatant to obtain a purified fibrinogen
concentrate, and recovering the purified fibrinogen concentrate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:138854 USPATFULL

TITLE: Fibrinogen concentrate obtained from blood plasma,

INVENTOR(S) : process and plant for its preparation
Laub, Ruth, Brussels, Belgium
Wael, Luc De, Ranst, Belgium
PATENT ASSIGNEE(S) : Croix-Rouge de Belgique, Brussels, Belgium (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5834420		19981110
	WO 9602571		19960201
APPLICATION INFO.:	US 1997-765838		19970707 (8)
	WO 1995-BE69		19950714
			19970707 PCT 371 date
			19970707 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1995-94870121	19950823
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Tsang, Cecilia J.	
ASSISTANT EXAMINER:	Marshall, S. G.	
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson and Bear, LLP	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	553	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 17 OF 44 USPATFULL on STN
TI Antiplasma animal model
AB There is disclosed an anti-plasma antibody preparation for treatment of a mammal, which preparation is capable of directly or indirectly inhibiting and/or eliminating several blood factors, a method of producing such a preparation and a method of evaluating substances for treating clotting disorders by using said anti-plasma antibody preparation. There is further disclosed a method of determining the bleeding characteristics of a mammal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 1998:107999 USPATFULL
TITLE: Antiplasma animal model
INVENTOR(S) : Eibl, Johann, Vienna, Austria
Turecek, Peter, Klosterneuburg Weidling, Austria
Schwarz, Hans Peter, Vienna, Austria
PATENT ASSIGNEE(S) : Immuno Aktiengesellschaft, Vienna, Austria (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804159		19980908
APPLICATION INFO.:	US 1996-663031		19960607 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	AT 1995-987	19950609
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chambers, Jasmine C.	
ASSISTANT EXAMINER:	Hauda, Karen M.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 7 Drawing Page(s)	

LINE COUNT: 737
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 44 USPATFULL on STN
TI Process for preparing a concentrate of blood coagulation factor
VIII-von willebrand factor
complex from total plasma
AB The invention relates to a process for preparing a concentrate of
Factor VIII-von Willebrand
factor complex having high specific activity from
total (non-cryoprecipitated) plasma.

The process comprises pre-purifying by means of a double treatment with
barium chloride and with aluminium hydroxide.

The process then comprises purification by chromatography on
an anion exchange resin, of the DEAE-Fractogel type.

The process includes a step of viral inactivation by means of a
treatment with solvent-detergent.

The process also makes it possible to recover fibrinogen, albumin,
immunoglobulins, antithrombin III, fibronectin and prothrombin complex,
from the same plasma.

The different concentrates obtained using the process according to the
invention are intended, in particular, for therapeutic use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:96964 USPATFULL
TITLE: Process for preparing a concentrate of blood
coagulation factor VIII-von
willebrand factor complex
from total plasma
INVENTOR(S): Burnouf-Radosevich, Miryana, Wavrin, France
Burnouf, Thierry, Wavrin, France
PATENT ASSIGNEE(S): Centre Regional de Transfusion Sanguine de Lille,
Lille, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679776		19971021
APPLICATION INFO.:	US 1990-577368		19900905 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1989-11567	19890905
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Hendricks, Keith D.	
ASSISTANT EXAMINER:	Moore, W.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	406	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 44 USPATFULL on STN
TI ELISA using multi-species antibodies for detection of von Willebrand
factor in multiple species
AB The subject invention provides an antibody directed to von Willebrand
factor antigen characterized by being capable of recognizing an epitope
of the von Willebrand factor antigen, the epitope being evolutionarily
conserved among vertebrate species. The subject invention further

provides a method for the qualitative and quantitative detection of von Willebrand factor in multiple species using an enzyme-linked immunosorbent assay and the antibodies of the subject invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 93:29142 USPATFULL
TITLE: ELISA using multi-species antibodies for detection of von Willebrand factor in multiple species
INVENTOR(S): Benson, Roger E., Albany, NY, United States
Catalfamo, James L., South Bethlehem, NY, United States
Dodds, W. Jean, Santa Monica, CA, United States
PATENT ASSIGNEE(S): Health Research, Incorporated, Albany, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5202264		19930413
APPLICATION INFO.:	US 1990-604885		19901026 (7)
DISCLAIMER DATE:	20100323		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-428161, filed on 11 Jan 1990		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nucker, Christine M.		
ASSISTANT EXAMINER:	Woodward, M. P.		
LEGAL REPRESENTATIVE:	Heslin & Rothenberg		
NUMBER OF CLAIMS:	82		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 12 Drawing Page(s)		
LINE COUNT:	2442		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 44 USPATFULL on STN
TI Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AB Novel polypeptides having Factor VIII activity are provided as well as compositions and methods for their preparation. The polypeptides comprise derivatives and fragments of Factor VIII and have sequences substantially similar to portions of naturally occurring Factor VIII. The polypeptides find use in treatment of Hemophilia A.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 92:103157 USPATFULL
TITLE: Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
INVENTOR(S): van Ooyen, Albert J. J., Voorburg, Netherlands
Pannekoek, Hans, Aalsmeer, Netherlands
Verbeet, Martinus P., Amsterdam, Netherlands
van Leen, Robert W., Nijmegen, Netherlands
PATENT ASSIGNEE(S): Gist-Brocades N.W., Delft, Netherlands (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5171844		19921215
APPLICATION INFO.:	US 1988-205226		19880610 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1987-201121	19870612
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Wax, Robert A.
ASSISTANT EXAMINER: Baker, R. Keith
LEGAL REPRESENTATIVE: Rae-Venter, Barbara
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Figure(s); 12 Drawing Page(s)
LINE COUNT: 1081
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 21 OF 44 USPATFULL on STN
TI **Purification** of von Willebrand Factor by affinity chromatography
AB A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 91:28708 USPATFULL
TITLE: **Purification** of von Willebrand Factor by affinity chromatography
INVENTOR(S): Newman, Jack, Burke, VA, United States
Farb, David L., Woodbridge, VA, United States
PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., Fort Washington, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5006642		19910409
APPLICATION INFO.:	US 1988-205881		19880613 (7)
RELATED APPLN. INFO.:	Division of Ser. No. US 1987-67990, filed on 29 Jun 1987, now patented, Pat. No. US 4774323		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Moskowitz, Margaret		
ASSISTANT EXAMINER:	Furman, Keith C.		
LEGAL REPRESENTATIVE:	Balogh, Imre (Jim), Nicholson, James A.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	415		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 44 USPATFULL on STN
TI Biologically active fragments of human antihemophilic factor and method for preparation thereof
AB Novel, biologically active fragments of human antihemophilic factor, processes for their preparation, pharmaceutical preparations containing them and the use of such fragments in the treatment of patients suffering from hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 89:89037 USPATFULL
TITLE: Biologically active fragments of human antihemophilic factor and method for preparation thereof
INVENTOR(S): Andersson, Lars-Olof, Knivsta, Sweden
Forsman, Nanna, Jarfalla, Sweden
Larsen, Kerstin E. I., Lidingo, Sweden
Lundin, Annelie B., Stockholm, Sweden
Pavlu, Bohdan, Huddinge, Sweden
Sandberg, Inga H., SpÅnga, Sweden
Sewerin, Karin M., Bromma, Sweden
PATENT ASSIGNEE(S): Kabivitrum AB, Stockholm, Sweden (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 4877614 19891031
APPLICATION INFO.: US 1988-185629 19880425 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1985-1050	19850305
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kight, John	
ASSISTANT EXAMINER:	Nutter, Nathan M.	
LEGAL REPRESENTATIVE:	Pollock, Vande Sande & Priddy	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	2	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	881	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 44 USPATFULL on STN
TI Flouroplastic immunoaffinity columns for **purification** of blood proteins
AB The present invention is a protein **purification** column comprising an organic substrate matrix having low reactivity to proteins, said matrix being capable of maintaining monoclonal antibodies attached thereto in an external configuration and preventing interaction with the protein to be bound to the antibody, and a monoclonal antibody attached to the substrate, the monoclonal antibody having a specific affinity for the protein to be isolated.

The present invention also is a method for isolating and purifying specific protein from a solution, wherein

1. Protein-specific monoclonal antibody is attached to the organic substrate matrix described above to form an antibody-substrate conjugate; and

2. Protein to be isolated, in an appropriate buffer solution, is contacted with the antibody-substrate conjugate.

An appropriate buffer may be applied to remove non-antibody bound contaminants, followed by an appropriate eluting agent to remove the protein from the monoclonal antibody.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 89:39057 USPATFULL
TITLE: Flouroplastic immunoaffinity columns for **purification** of blood proteins
INVENTOR(S): Zimmerman, Theodore S., La Jolla, CA, United States
Fulcher, Carol A., La Jolla, CA, United States
PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4831118		19890516
APPLICATION INFO.:	US 1987-83670		19870807 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Moskowitz, Margaret		
ASSISTANT EXAMINER:	Kushan, Jeff P.		
LEGAL REPRESENTATIVE:	Morgan & Finnegan		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
LINE COUNT:	377		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 44 USPATFULL on STN
TI Biologically active fragments of human antihemophilic factor and method
for preparation thereof
AB Novel, biologically active fragments of human antihemophilic factor,
processes for their preparation, pharmaceutical preparations containing
them and the use of such fragments in the treatment of patients
suffering from hemophilia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 88:36116 USPATFULL
TITLE: Biologically active fragments of human antihemophilic
factor and method for preparation thereof
INVENTOR(S): Andersson, Lars-Olof, Knivsta, Sweden
Forsman, Nanna, Jarfalla, Sweden
Larsen, Kerstin E. I., Lidingo, Sweden
Lundin, Annelie B., Stockholm, Sweden
Pavlu, Bohdan, Huddinge, Sweden
Sandberg, Inga H., Spangnga, Sweden
Sewerin, Karin M., Bromma, Sweden
PATENT ASSIGNEE(S): KabiVitrum AB, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4749780		19880607
APPLICATION INFO.:	US 1986-835914		19860304 (6)

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1985-1050	19850305
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Phillips, Delbert R.	
ASSISTANT EXAMINER:	Nutter, Nathan M.	
LEGAL REPRESENTATIVE:	Pollock, Vande Sande & Priddy	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	608	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 44 USPATFULL on STN
TI Ultrapurification of factor VIII using monoclonal antibodies
AB A method of preparing high purity procoagulant protein comprising the
steps of (a) adsorbing a VIII:C/VIII:RP complex from a plasma or
commercial concentrate source of factor VIII onto agarose beads bound to
a monoclonal antibody specific to VIII:RP, (b) eluting VIII:C with a
salt solution, (c) adsorbing the eluted VIII:C on an animohexyl agarose
column and eluting the VIII:C with a salt solution.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 82:57885 USPATFULL
TITLE: Ultrapurification of factor VIII using monoclonal
antibodies
INVENTOR(S): Zimmerman, Theodore S., La Jolla, CA, United States
Fulcher, Carol A., La Jolla, CA, United States
PATENT ASSIGNEE(S): Scripps Clinic and Research Foundation, La Jolla, CA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4361509		19821130
APPLICATION INFO.:	US 1981-330105		19811214 (6)
DOCUMENT TYPE:	Utility		

FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 596
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 44 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Application of a new statistical approach to optimize the
immunopurification of antihemophilia A factor.

AB Our aim was to optimize the immunopurification process of human factor
VIII. This **purification** was performed using a mouse monoclonal
anti-factor VIII light-chain antibody. Previous dissociation of the
factor VIII-von Willebrand
factor complex with CaCl₂ led to a 50% increase of the
factor VIII adsorption on the immunosorbent. The optimization of the
elution step required the analysis of the effects of two parameters, pH
and ionic strength, on four different responses: elution yield,
concentration, specific activity and stability of factor VIII. For this
purpose, a multifunctional method using Doehlert matrices for
statistically designed experiments was applied. This methodology allowed
us to obtain, with only seven experiments, a 60% increase of the elution
yield and a two-fold increase of the specific activity of factor VIII.

ACCESSION NUMBER: 93041514 EMBASE

DOCUMENT NUMBER: 1993041514

TITLE: Application of a new statistical approach to optimize the
immunopurification of antihemophilia A factor.

AUTHOR: Bihoreau N.; Layet S.; Fontaine-Aupart M.P.; Paolantonacci
P.

CORPORATE SOURCE: Centre Nat. de Transfusion Sanguine, 3 Avenue des
Tropiques, 91943 Les Ulis Cedex, France

SOURCE: Journal of Chromatography - Biomedical Applications, (1993)
612/1 (49-56).

ISSN: 0378-4347 CODEN: JCBADL

COUNTRY: Netherlands

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 025 Hematology
029 Clinical Biochemistry
037 Drug Literature Index

LANGUAGE: English

SUMMARY LANGUAGE: English

L4 ANSWER 27 OF 44 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Characteristics of the von Willebrand factor in virus inactivated F VIII
concentrates: The impact of heat treatment.

AB The known transmission of viral diseases, particularly AIDS (HIV, LAV,
HTLV-III), has led to the mandatory use of virus-inactivated coagulation
factor concentrates for treatment of bleeding disorders due to deficient
or abnormal synthesis of the **factor VIII/von**
Willebrand factor complex. The present
investigation was undertaken to study the influence of heat-treatment on
the von Willebrand factor (vWf). Using normal plasma as reference
material, we studied the influence of low-**purification** steps in
a simple cryo-plasma and a unrefined freeze-dried cryoprecipitate. For
comparison, non-heated and heat-inactivated concentrates of different
manufacture representing varying heat-treatment protocols were studied
using quantitation of von Willebrand factor antigen (vWf:Ag) by
electroimmunoassay and ELISA, and investigation of vWf multimeric
composition. A locally produced factor VIII concentrate was studied before
and after exposure to 68°C for 72 hours (dry state). Whenever
possible, commercial preparations manufactured prior to the heat-treatment
era were compared with the present product. The locally produced high

purity concentrate elicited only minor changes in oligomeric satellite pattern, which did not change after dry heat exposure. In principle, no major differences were found between non-heated and pasteurized commercial concentrates of same manufactural origin.

ACCESSION NUMBER: 87163210 EMBASE
DOCUMENT NUMBER: 1987163210
TITLE: Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: The impact of heat treatment.
AUTHOR: Ingerslev J.; Bukh A.; Wallevik K.; et al.
CORPORATE SOURCE: Department of Clinical Immunology, University Hospital Aarhus, DK-8000 Aarhus C, Denmark
SOURCE: Thrombosis Research, (1987) 47/2 (175-182).
CODEN: THBRAA
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 047 Virology
025 Hematology
LANGUAGE: English

L4 ANSWER 28 OF 44 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Application of a new statistical approach to optimize the immunopurification of antihemophilia A factor.
AB Our aim was to optimize the immunopurification process of human factor VIII. This **purification** was performed using a mouse monoclonal anti-factor VIII light-chain antibody. Previous dissociation of the **factor VIII-von Willebrand factor complex** with CaCl₂ led to a 50% increase of the factor VIII adsorption on the immunosorbent. The optimization of the elution step required the analysis of the effects of two parameters, pH and ionic strength, on four different responses: elution yield, concentration, specific activity and stability of factor VIII. For this purpose, a multifunctional method using Doehlert matrices for statistically designed experiments was applied. This methodology allowed us to obtain, with only seven experiments, a 60% increase of the elution yield and a two-fold increase of the specific activity of factor VIII.

ACCESSION NUMBER: 1993:207726 BIOSIS
DOCUMENT NUMBER: PREV199395108951
TITLE: Application of a new statistical approach to optimize the immunopurification of antihemophilia A factor.
AUTHOR(S): Bihoreau, N. [Reprint author]; Layet, S.; Fontaine-Aupart, M. P.; Paolantonacci, P.
CORPORATE SOURCE: Centre National de Transfusion Sanguine, 3 Avenue des Tropiques, B.P. 100, 91943 Les Ulis Cedex, France
SOURCE: Journal of Chromatography Biomedical Applications, (1993) Vol. 612, No. 1, pp. 49-56.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 23 Apr 1993
Last Updated on STN: 24 Apr 1993

L4 ANSWER 29 OF 44 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI CHARACTERISTICS OF THE VON WILLEBRAND FACTOR IN VIRUS INACTIVATED F VIII CONCENTRATES THE IMPACT OF HEAT TREATMENT.
AB The known transmission of viral diseases, particularly AIDS(HIV, LAV, HTLV-III), has led to the mandatory use of virus-inactivated coagulation factor concentrates for treatment of bleeding disorders due to deficient or abnormal synthesis of the **factor VIII/von Willebrand factor complex**. The present investigation was undertaken to study the influence of heat-treatment on the von Willebrand factor (vWf). Using normal plasma as reference material, we studied the influence of low-**purification** steps in a simple cryo-plasma and a unrefined freeze-dried cryoprecipitate. For comparison, non-heated and heat-inactivated concentrates of different

manufacture representing varying heat-treatment protocols were studied using quantitation of von Willebrand factor antigen (vWf:Ag) by electroimmunoassay and ELISA, and investigation of vWf multimeric composition. A locally produced factor VIII concentrate was studied before and after exposure to 68° C for 72 hours (dry state). Whenever possible, commercial preparations manufactured prior to the heat-treatment era were compared with the present product. The locally produced high purity concentrate elicited only minor changes in oligomeric satellite pattern, which did not change after dry heat exposure. In principle, no major differences were found between non-heated and pasteurized commercial concentrates of same maufactural origin.

ACCESSION NUMBER: 1987:380664 BIOSIS
DOCUMENT NUMBER: PREV198784067161; BA84:67161
TITLE: CHARACTERISTICS OF THE VON WILLEBRAND FACTOR IN VIRUS
INACTIVATED F VIII CONCENTRATES THE IMPACT OF HEAT
TREATMENT.
AUTHOR(S): INGERSLEV J [Reprint author]; BUKH A; WALLEVIK K; MOLLER N
P H; STENBJERG S
CORPORATE SOURCE: DEP CLINICAL IMMUNOL, UNIV HOSP AARHUS, DK-8000 AARHUS C,
DENMARK
SOURCE: Thrombosis Research, (1987) Vol. 47, No. 2, pp. 175-182.
CODEN: THBRAA. ISSN: 0049-3848.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
ENTRY DATE: Entered STN: 5 Sep 1987
Last Updated on STN: 5 Sep 1987

L4 ANSWER 30 OF 44 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
TI Simple, quick and high-yielding **purification** of blood
coagulation factor VIII and its von Willebrand factor complex from highly
concentrated solution in high purity, for use as anti-thrombotic.
AN 2000-647421 [62] WPIDS
AB WO 200061633 A UPAB: 20001130
NOVELTY - A method for purifying blood coagulation **factor**
VIII/von Willebrand factor
complex comprises mixing a solution containing the complex with a
gel and then separating and removing the gel from the solution.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a
method for purifying blood coagulation factor VIII comprising the
dissociation of the complex before ultrafiltration of the mixture.
ACTIVITY - Thrombolytic.
MECHANISM OF ACTION - Anti-thrombotic agent.
USE - The prepared blood coagulation factor VIII can be used as an
anti-thrombotic.
ADVANTAGE - The method is simple, quick and high yielding to give
blood coagulation factor VIII in high purity.
Dwg.0/0

ACCESSION NUMBER: 2000-647421 [62] WPIDS
DOC. NO. CPI: C2000-195911
TITLE: Simple, quick and high-yielding **purification** of
blood coagulation factor VIII and its von Willebrand
factor complex from highly concentrated solution in high
purity, for use as anti-thrombotic.
DERWENT CLASS: B04
INVENTOR(S): HOSOKAWA, K; NAGATA, M; SUZUKI, T
PATENT ASSIGNEE(S): (CHCC) CHISSO CORP; (FUJO) FUJIMORI KOGYO KK; (FUJO)
FUJIMORI IND CO LTD
COUNTRY COUNT: 92
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2000061633	A1	20001019	(200062)*	JA	28

RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SL SZ TZ UG ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ
 EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
 LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI
 SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000036767 A 20001114 (200108)
 JP 2000611574 X 20020723 (200263)
 JP 2002348300 A 20021204 (200310) 7

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000061633	A1	WO 2000-JP2350	20000411
AU 2000036767	A	AU 2000-36767	20000411
JP 2000611574	X	JP 2000-611574	20000411
		WO 2000-JP2350	20000411
JP 2002348300	A	JP 1999-104587	19990412

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000036767	A Based on	WO 2000061633
JP 2000611574	X Based on	WO 2000061633

PRIORITY APPLN. INFO: JP 1999-104587 19990412

L4 ANSWER 31 OF 44 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI **Extracting factor VIII - von**

Willebrand factor complex from plasma -

comprises stabilisation, selective absorption, extraction and
purification, used for treatment of haemophilia A.

AN 1994-177817 [22] WPIDS

AB EP 600480 A UPAB: 19940722

A process for extracting Factor VIII - von willebrand factor (FVIII:C-FvW) complex from total human plasma comprises: (a) stabilising unfrozen plasma (at room temperature) with antiprotease, or a basic amino acids or wino acids, containing thiolic or indolic gps.; diluted in sterile and apyrogenic distilled water, in a volume of Ca, 1/2 to 1/10th of the volume of the plasma; (b) treating the mixture with an anionic exchange resin conditioned to separate the factors constituting the protrombinic compld (PTC); (c) stabilising the PTC plasma supernatant with heparin and feeding into a chromatographic column containing an anionic exchange resin suitably conditioned; (d) eluting the adsorbed Factor VIII:C - FvW complex upon the column and collecting the solution and stabilising it with heparin and polyethylene glycol (PEG) and treating it with an aluminium hydroxide, Al(OH)₃, suspension; (e) filtering the supernatant containing Factor VIII:C-FvW and restoring osmolarity conditions in the solution, then subjecting it to viral inactivation; (f) feeding the solution into a chromatographic column, containing a conditioned cationic exchange resin; and (g) eluting the adsorbed Factor VIII:C-FvW complex and bringing the solution obtained to physiologic condition, concentrate and dispensing into vials and lyophilising.

USE - This method is useful for producing large quantities of Factor VIII concentrates for prophylaxis and treatment of haemophilia A.

Dwg.0/0

ACCESSION NUMBER: 1994-177817 [22] WPIDS

DOC. NO. CPI: C1994-081287

TITLE: **Extracting factor VIII - von**

Willebrand factor complex

from plasma - comprises stabilisation, selective
 absorption, extraction and **purification**, used

for treatment of haemophilia A.
 DERWENT CLASS: B04
 INVENTOR(S): ARRIGHI, S; BORRI, M G; BUCCI, E
 PATENT ASSIGNEE(S): (AIMA-N) AIMA-DERIVATI SPA; (ISTS) SCLAVO SPA; (ISIS-N) ISI IST SIEROVACCINOGENO ITAL SPA
 COUNTRY COUNT: 11
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 600480	A2	19940608	(199422)*	EN	5
R: AT CH DE DK ES FR GB IT LI NL SE					
EP 600480	A3	19941123	(199536)		
IT 1256622	B	19951212	(199627)		
EP 600480	B1	20000906	(200044)	EN	
R: AT CH DE DK ES FR GB IT LI NL SE					
DE 69329371	E	20001012	(200059)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 600480	A2	EP 1993-119439	19931202
EP 600480	A3	EP 1993-119439	19931202
IT 1256622	B	IT 1992-MI2778	19921204
EP 600480	B1	EP 1993-119439	19931202
DE 69329371	E	DE 1993-629371	19931202
		EP 1993-119439	19931202

FILING DETAILS:

PATENT NO	KIND	PATENT NO
DE 69329371	E Based on	EP 600480

PRIORITY APPLN. INFO: IT 1992-MI2778 19921204

L4 ANSWER 32 OF 44 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
 TI Improved purificn. of von Willebrand Factor - by mild incubation step to increase therapeutic activity.
 AN 1991-124951 [17] WPIDS
 CR 1988-292490 [41]; 1996-200346 [20]; 1998-109871 [10]
 AB US 5006642 A UPAB: 19980309
 In a method for increasing the therapeutic activity of von Willebrand Factor, an essentially purified von Willebrand Factor is obtd. by adsorbing a **Factor VIII/von Willebrand Factor complex** obtd. from plasma or commercial concentrate source onto particles bound to a monoclonal or polyclonal antibody specific to von Willebrand Factor; first eluting Factor VIII from the particles bound to a monoclonal or polyclonal antibody specific to von Willebrand Factor; first eluting Factor VIII from the particles; next eluting von Willebrand Factor from the particles by washing the particles with a 0.05 M to 5 M aqueous solution of a chaotropic agent; and separating the von Willebrand factor from the chaotropic agent. The essentially purified von Willebrand Factor is then incubated at a temperature of 20deg.C to 55deg.C for 1 to 30 hours
 ACCESSION NUMBER: 1991-124951 [17] WPIDS
 CROSS REFERENCE: 1988-292490 [41]; 1996-200346 [20]; 1998-109871 [10]
 DOC. NO. CPI: C1991-053933
 TITLE: Improved purificn. of von Willebrand Factor - by mild incubation step to increase therapeutic activity.
 DERWENT CLASS: B04
 INVENTOR(S): FARB, D L; NEWMAN, J
 PATENT ASSIGNEE(S): (RHON) RHONE-POULENC RORER

COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 5006642	A	19910409	(199117)*		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 5006642	A	US 1988-205881	19880613

PRIORITY APPLN. INFO: US 1988-205881 19880613; US
1987-67990 19870629

L4 ANSWER 33 OF 44 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN

TI Preparation of **factor VIII-von-willebrand factor complex** concentrate - by pre-purifying whole plasma with barium chloride and aluminium hydroxide then purifying by chromatography on anion exchange resin.

AN 1991-075455 [11] WPIDS

AB EP 416983 A UPAB: 19930928

A process for the preparation of a stable Factor VIII-von Willebrand factor concentrate with a high specific activity is claimed. The process involves pre-purifying whole blood plasma by a double treatment with barium chloride and aluminium hydroxide and purifying by chromatography using an anion exchange resin which allows retention of very large molecules. The plasma may be fresh or frozen. The plasma may be added to a stabilising mixture containing 2.0-2 micro/ml heparin, 1-5 mM EDTA and 1-10 mM CaCl₂, optionally with glucose at a concentration of 5-60 g/l. The pre-purification preferably comprises precipitation from barium chloride followed by centrifugation and recuperation of the supernatant; adsorption on aluminium hydroxide gel followed by cold centrifugation and recuperation of the supernatant, and finally a de-salting treatment. Factor VIII-von Willebrand factor concentrates and protein concentrates derived from the plasma are also claimed, as is their therapeutic usage.

USE/ADVANTAGE - In the treatment of haemophilia the process is simple and gives a high purity, stable concentration in good yield. Since the plasma does not need prior cryoprecipitation, losses of Factor VIII are reduced. The pre-purification step eliminates the constituents of the prothrombinic complex (Factors II, VII, IX, X).
0/0

ABEQ EP 416983 B UPAB: 19931118

Process for preparing a stable concentrate of the Factor VIII-von Willebrand factor having high specific activity, characterised in that a total plasma is subjected to pre-purification by a double treatment which comprises precipitation with barium chloride and adsorption on aluminium hydroxide gel and to purification by chromatography on an anion exchange gel permitting the retention of very large molecules.
Dwg. 0/0

ABEQ US 5679776 A UPAB: 19971209

A process for preparing a stable concentrate of a **Factor VIII-von Willebrand factor complex** which comprises:

- (a) contacting non-cryoprecipitated total plasma with barium chloride and collecting a first supernatant;
- (b) contacting said first supernatant with aluminum hydroxide gel;
- (c) centrifuging and collecting a second supernatant;
- (d) de-salting said second supernatant;
- (e) contacting said second supernatant with an anion exchange gel, comprising a copolymer of oligoethylene glycol, glycine methacrylate, and

pentaerythrol-dimethacrylate; and

(f) collecting said stable concentrate of **Factor**

VIII-von Willebrand factor

complex.

Dwg.0/0

ACCESSION NUMBER: 1991-075455 [11] WPIDS

DOC. NO. CPI: C1991-032009

TITLE: Preparation of **factor VIII-von-willebrand factor complex**

concentrate - by pre-purifying whole plasma with barium chloride and aluminium hydroxide then purifying by chromatography on anion exchange resin.

DERWENT CLASS: B04

INVENTOR(S): BURNOUF, T; BURNOUF-RADOSEVICH, M; BURNOUF, THIERRY B T; BURNOUFRAD, M

PATENT ASSIGNEE(S): (REGI-N) CENT REGIONAL TRANSFUSION SANGUINE; (REGI-N) CENT REG TRANS SANG; (BURN-I) BURNOUF-RADOSEVICH; (REGI-N) CENT REGIONAL TRANS; (REGI-N) CENT REGIONAL TRANSFUSION SANGUINE LILLE

COUNTRY COUNT: 27

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
EP 416983	A	19910313	(199111)*		
R: AT BE CH DE ES FR GB GR IT LI LU NL SE					
NO 9003865	A	19910306	(199119)		
CA 2024667	A	19910306	(199120)		
FR 2651437	A	19910308	(199120)		
FI 9004381	A	19910306	(199123)		
HU 56858	T	19911028	(199147)		
BR 9004626	A	19920324	(199217)		
AU 9062218	A	19920312	(199220)		
JP 04124199	A	19920424	(199223)#		7
DD 298110	A5	19920206	(199227)		
CZ 9004312	A3	19930113	(199319)		
EP 416983	B1	19930728	(199330)	FR	9
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 69002427	E	19930902	(199336)		
CZ 277939	B6	19930616	(199337)		
ES 2057475	T3	19941016	(199442)		
RU 2025129	C1	19941230	(199531)		6
FI 95654	B	19951130	(199601)		
NO 178716	B	19960212	(199611)		
US 5679776	A	19971021	(199748)		5
SK 279367	B6	19981007	(199850)		
SK 9004312	A3	19981007	(199850)		
JP 2931655	B2	19990809	(199937)#		6
KR 168415	B1	19990115	(200038)#		
CA 2024667	C	20010731	(200147)	EN	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 416983	A	EP 1990-402395	19900830
FR 2651437	A	FR 1989-11567	19890905
AU 9062218	A	AU 1990-62218	19900906
DD 298110	A5	DD 1990-343869	19900905
CZ 9004312	A3	CS 1990-4312	19900905
EP 416983	B1	EP 1990-402395	19900830
DE 69002427	E	DE 1990-602427	19900830
		EP 1990-402395	19900830
CZ 277939	B6	CS 1990-4312	19900905

ES 2057475	T3	EP 1990-402395	19900830
RU 2025129	C1	SU 1990-4831275	19900904
FI 95654	B	FI 1990-4381	19900905
NO 178716	B	NO 1990-3865	19900905
US 5679776	A	US 1990-577368	19900905
SK 279367	B6	CS 1990-4312	19900905
SK 9004312	A3	CS 1990-4312	19900905
JP 2931655	B2	JP 1990-240177	19900912
KR 168415	B1	KR 1990-14264	19900910
CA 2024667	C	CA 1990-2024667	19900905

FILING DETAILS:

PATENT NO	KIND	PATENT NO
DE 69002427	E Based on	EP 416983
CZ 277939	B6 Previous Publ.	CS 9004312
ES 2057475	T3 Based on	EP 416983
FI 95654	B Previous Publ.	FI 9004381
NO 178716	B Previous Publ.	NO 9003865
SK 279367	B6 Previous Publ.	SK 9004312
JP 2931655	B2 Previous Publ.	JP 04124199

PRIORITY APPLN. INFO: FR 1989-11567 19890905; KR
1990-14264 19900910

L4 ANSWER 34 OF 44 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI Isolation of the **factor VIII - von Willebrand factor complex** directly from plasma by gel filtration

AB A high capacity gel filtration system was developed with the purpose of isolating factor VIII (FVIII) and von Willebrand factor (VWF) directly from plasma in significantly higher yields than obtained by cryoprecipitation, the technique most commonly used to recover FVIII-VWF from human plasma. After laboratory-scale gel filtration of plasma, a FVIII-containing fraction was collected containing about 90% of FVIII in the applied plasma and with almost tenfold higher purity than that obtained by cryoprecipitation. The gel filtration step has been scaled up for use as the initial step in the manufacturing process for a FVIII preparation (Nordiate). (C) 1998 Elsevier Science B.V. All rights reserved.

ACCESSION NUMBER: 1998:792752 SCISEARCH

THE GENUINE ARTICLE: 127HP

TITLE: Isolation of the **factor VIII - von Willebrand factor complex** directly from plasma by gel filtration

AUTHOR: Kaersgaard P (Reprint); Barington K A

CORPORATE SOURCE: HEMASURE DENMARK AS, SAUNTESVEJ 13, DK-2820 GENTOFTE, DENMARK (Reprint)

COUNTRY OF AUTHOR: DENMARK

SOURCE: JOURNAL OF CHROMATOGRAPHY B, (18 SEP 1998) Vol. 715, No. 2, pp. 357-367.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0378-4347.

DOCUMENT TYPE: Article; Journal

FILE SEGMENT: LIFE

LANGUAGE: English

REFERENCE COUNT: 34

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 35 OF 44 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN

TI APPLICATION OF A NEW STATISTICAL APPROACH TO OPTIMIZE THE IMMUNOPURIFICATION OF ANTIHEMOPHILIA-A FACTOR

AB Our aim was to optimize the immunopurification process of human factor VIII. This **purification** was performed using a mouse monoclonal anti-factor VIII light-chain antibody. Previous dissociation of the **factor VIII-von Willebrand factor complex** with CaCl₂ led to a 50% increase of the factor VIII adsorption on the immunosorbent. The optimization of the elution step required the analysis of the effects of two parameters, pH and ionic strength, on four different responses: elution yield, concentration, specific activity and stability of factor VIII. For this purpose, a multifunctional method using Doehlert matrices for statistically designed experiments was applied. This methodology allowed us to obtain, with only seven experiments, a 60% increase of the elution yield and a two-fold increase of the specific activity of factor VIII.

ACCESSION NUMBER: 93:122175 SCISEARCH
THE GENUINE ARTICLE: KN624
TITLE: APPLICATION OF A NEW STATISTICAL APPROACH TO OPTIMIZE THE IMMUNOPURIFICATION OF ANTIHEMOPHILIA-A FACTOR
AUTHOR: BIHOREAU N (Reprint); LAYET S; FONTAINEAUPART M P; PAOLANTONACCI P
CORPORATE SOURCE: INST MERIEUX, CTR NATL TRANSFUS SANGUINE, 3 AVE TROPIQUES, BP 100, F-91943 LES ULIS, FRANCE (Reprint); UNIV PARIS 11, PHOTOPHYS MOLEC LAB, UPR 3361, F-91405 ORSAY, FRANCE
COUNTRY OF AUTHOR: FRANCE
SOURCE: JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, (29 JAN 1993) Vol. 612, No. 1, pp. 49-56.
ISSN: 0378-4347.
DOCUMENT TYPE: Article; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: 30

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L4 ANSWER 36 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Blood coagulation factor VIII and blood coagulation **factor VIII/von Willebrand factor complex purification** method with gel filtration

AB A method for purifying a blood coagulation factor VIII/Von Willebrand factor (FVIII/vWF) complex and blood coagulation factor VIII (FVIII) via a simple step even from a solution containing a large amount of the blood coagulation

factor VIII/Von Willebrand factor complex, is disclosed. This method comprises mixing a solution containing the blood coagulation **factor VIII /Von Willebrand factor complex** with a gel and then separating and removing the gel from the solution Use of dry gel and gel filtration chromatog. possibly in combination with anhydro-thrombin affinity chromatog. in this method is claimed. FVIII/vWF complex was purified using dry Sephacryl-300 gel and Sepharose 6B gel filtration chromatog., dry Sepharose 6B and Sephacryl-400 gel filtration chromatog., or Sephacryl-4B gel filtration chromatog. Impurities such as fibrinogen and fibronectin were removed.

ACCESSION NUMBER: 2000:742141 HCAPLUS
DOCUMENT NUMBER: 133:278346
TITLE: Blood coagulation factor VIII and blood coagulation **factor VIII/von Willebrand factor complex purification** method with gel filtration
INVENTOR(S): Hosokawa, Kazuya; Suzuki, Toyoaki; Nagata, Masanori
PATENT ASSIGNEE(S): Fujimori Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

bad date

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061633	A1	20001019	WO 2000-JP2350	20000411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2002348300	A2	20021204	JP 1999-104587	19990412
PRIORITY APPLN. INFO.:			JP 1999-104587	A 19990412
REFERENCE COUNT:	32	THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 37 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

 TI Chromatographic purification of factor VIII/
 von Willebrand factor complex

 AB The invention relates to a method for the production of factor VIII:C/von
 Willebrand factor complex from plasma or a plasma fraction by chromatog.
 on a cation exchanger, wherein the factor VIII:C/von Willebrand factor
 complex is obtained with at least 300 times the purity of the plasma and
 the yield of factor VIII:C and the von Willebrand factor is at least 50 %
 in relation to cryoppts. or analogous plasma fractions. The purification is
 achieved in a single step; the process is combined with antiviral
 treatment, e.g. addition of organic solvents and/or detergents, ultrafiltration
 etc. Thus factor VIII/von
 Willebrand factor complex was purified from
 cryoppt. with 62%/68% yield and a 450-fold purification using Fractogel
 EMD-SO3- and a solution of Triton X100 and tri(n-butyl)phosphate.

ACCESSION NUMBER: 1999:566081 HCAPLUS

DOCUMENT NUMBER: 131:167367

 TITLE: Chromatographic purification of
 factor VIII/von
 Willebrand factor complex

INVENTOR(S): Linnau, Yendra; Schonhofer, Wolfgang

PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Austria

SOURCE: PCT Int. Appl., 15 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943712	A1	19990902	WO 1999-AT48	19990225
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 9838220	A1	19980903	WO 1998-AT43	19980227
W: AU, BR, CA, CZ, HU, IL, JP, MX, NO, PL, RU, SI, SK, US RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

AT 9800866	A	20010415	AT 1998-866	19980520
AT 408443	B	20011126		
AU 9925030	A1	19990915	AU 1999-25030	19990225
EP 1056779	A1	20001206	EP 1999-904614	19990225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002504561	T2	20020212	JP 2000-533462	19990225
US 6605222	B1	20030812	US 2001-623245	20010319

PRIORITY APPLN. INFO.:
 WO 1998-AT43 W 19980227
 AT 1998-866 A 19980520
 AT 1997-338 A 19970227
 WO 1999-AT48 W 19990225

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

TI **Purification of factor VIII/von Willebrand factor complex** by cation-exchange chromatography

AB A method of purifying the factor VIII/von Willebrand factor (vWF) complex by cation-exchange chromatog. is described. Complex bound to a cation-exchanger is eluted with a salt gradient to release factor VIII/vWF complex especially complexes containing vWF multimers. The method can be used on crude preps., such as blood cryoppts., but is most effective when the protein is partially purified, e.g. by anion-exchange chromatog. The preferred cation exchanger is an acid form of Fractogel EMD. Purifications of >300-fold and yields of >50% are obtained.

ACCESSION NUMBER: 1998:608647 HCAPLUS
 DOCUMENT NUMBER: 129:213514
 TITLE: **Purification of factor VIII/von Willebrand factor complex** by cation-exchange chromatography

INVENTOR(S): Mitterer, Artur; Fischer, Bernhard; Schonberger, Oyvning L.; Thomas-Urban, Kathrin; Dorner, Friedrich; Eibl, Johann

PATENT ASSIGNEE(S): Immuno A.-G., Austria
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9838220	A1	19980903	WO 1998-AT43	19980227
W: AU, BR, CA, CZ, HU, IL, JP, MX, NO, PL, RU, SI, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AT 9700338	A	19990915	AT 1997-338	19970227
AT 406373	B	20000425		
AU 9860806	A1	19980918	AU 1998-60806	19980227
AU 744919	B2	20020307		
EP 971958	A1	20000119	EP 1998-905132	19980227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, IE, SI, FI				
JP 2001517212	T2	20011002	JP 1998-537060	19980227
AT 9800866	A	20010415	AT 1998-866	19980520
AT 408443	B	20011126		
WO 9943712	A1	19990902	WO 1999-AT48	19990225
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				

TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9925030 A1 19990915 AU 1999-25030 19990225
EP 1056779 A1 20001206 EP 1999-904614 19990225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
JP 2002504561 T2 20020212 JP 2000-533462 19990225
NO 9904137 A 19990826 NO 1999-4137 19990826
US 2002058625 A1 20020516 US 2001-3621 20011102
PRIORITY APPLN. INFO.: AT 1997-338 A 19970227
WO 1998-AT43 W 19980227
AT 1998-866 A 19980520
WO 1999-AT48 W 19990225
US 2000-367459 A3 20000508
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 39 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Immunoaffinity purification of von Willebrand factor or
factor VIII/von Willebrand
factor complex

AB A method for obtaining high-purity von Willebrand factor (vWF) or factor
VIII/vWF complex by immunoaffinity chromatog. is described. VWF or factor
VIII/vWF complex bound with an immune adsorbing agent is eluted with a
medium containing a zwitterion, e.g. an amino acid, as an essential active
part, while preserving the mol. integrity of the vWF or factor VIII/vWF
complex. The purified factor can be used in the treatment of hemophilia
A. Monoclonal antibodies were tested for their effectiveness in specific
and reversible binding of vWF and factor VIII complex. Amino acids were
tested for their effectiveness in elution of vWF with betaine the most
effective at neutral pH's and other non-polar also highly effective.

ACCESSION NUMBER: 1998:608645 HCAPLUS
DOCUMENT NUMBER: 129:213512
TITLE: Immunoaffinity purification of von
Willebrand factor or factor VIII/
von Willebrand factor
complex
INVENTOR(S): Mitterer, Artur; Fiedler, Christian; Fischer,
Bernhard; Dorner, Friedrich; Eibl, Johann
PATENT ASSIGNEE(S): Immuno A.-G., Austria
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9838218	A1	19980903	WO 1998-AT33	19980218
W: AU, BR, CA, CZ, HU, IL, JP, MX, NO, PL, RU, SI, SK, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AT 9700339	A	20000215	AT 1997-339	19970227
AT 406867	B	20001025		
AU 9861998	A1	19980918	AU 1998-61998	19980218
AU 734277	B2	20010607		
EP 1012191	A1	20000628	EP 1998-903938	19980218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, IE, SI, FI				
JP 2001513762	T2	20010904	JP 1998-537055	19980218
NO 9904084	A	19991019	NO 1999-4084	19990824
US 6579723	B1	20030617	US 1999-367362	19991021

PRIORITY APPLN. INFO.:

AT 1997-339 A 19970227

WO 1998-AT33 W 19980218

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 40 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Pilot immunoaffinity **purification** of factor VIII/vWF complex (preliminary results)

AB A standard purification procedure for the blood **Factor VIII/von Willebrand Factor complex** is described. It is based on an immunoaffinity chromatog. protocol.

ACCESSION NUMBER: 1993:665807 HCAPLUS

DOCUMENT NUMBER: 119:265807

TITLE: Pilot immunoaffinity **purification** of factor VIII/vWF complex (preliminary results)

AUTHOR(S): Van Wijngaarden, L.; Hoff, H. S.; Koops, K.; Van Weperen, J. J.; Das, P. C.; Sibinga, C. T. Smit

CORPORATE SOURCE: Bio-Intermediair B.V., Groningen, 9700 AL, Neth.

SOURCE: Colloque INSERM (1993), 227(Biotechnology of Blood Proteins), 109-14

CODEN: CINMDE; ISSN: 0768-3154

DOCUMENT TYPE: Journal

LANGUAGE: English

L4 ANSWER 41 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Immunoaffinity **purification** of **factor VIII/von Willebrand factor complex**

AB Preliminary results of the design of an immunoaffinity purification of the factor VIII/von Willebrand factor (vWF) complex are summarized. An overview of an approach on the development and screening for an anti-vWF antibody suitable in an immunoaffinity purification system is presented.

ACCESSION NUMBER: 1992:403089 HCAPLUS

DOCUMENT NUMBER: 117:3089

TITLE: Immunoaffinity **purification** of **factor VIII/von Willebrand factor complex**

AUTHOR(S): Koops, K.; Hoff, H. S.; Van Weperen, J. J.; Das, P. C.; Smit Sibinga, C. T.

CORPORATE SOURCE: Bio-Intermediair, Groningen, Neth.

SOURCE: Developments in Hematology and Immunology (1991), 26(Coagulation Blood Transfus.), 103-17

CODEN: DHIMDR; ISSN: 0167-9201

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

L4 ANSWER 42 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN

TI The **purification** of the VIII/vWF complex using dextran sulfate Sepharose chromatography

AB Factor VIII/vWF displays high affinity for matrix-bound dextran sulfate. Due attention to the flow rates has to be taken into consideration to achieve maximal binding. Typical yields of vWf:Ag are usually 70-90% expressing biol. activity and of normal multimeric distribution. Factor VIII:C can be copurified with vWf:Ag providing a sufficient concentration of free

Ca is present at 4°. Higher concns. of Ca (20 mM) lead to blockage of the columns. Normal yields of thrombin-activatable factor VIII are usually 40% VIII:C and 70% VIII:Ag. Alternatively, higher yields of VIII:C can be obtained (80% VIII:C and 100% VIII:Ag) by application of L-lysine gradients but with some loss of resolution between proteins. VIII:C has a vWf-independent affinity for DS. These matrixes demonstrate potential value in the fractionation of plasma or genetically engineered products.

ACCESSION NUMBER: 1990:11822 HCAPLUS

DOCUMENT NUMBER: 112:11822

TITLE: The **purification** of the VIII/vWF complex
using dextran sulfate Sepharose chromatography
AUTHOR(S): Harrison, P.; Saundry, R. H.; Savidge, G. F.
CORPORATE SOURCE: Rayne Inst., UMDS, London, SE1 7EH, UK
SOURCE: Colloque INSERM (1989), 175(Biotechnol. Proteines
Plasma), 279-85
CODEN: CINMDE; ISSN: 0768-3154
DOCUMENT TYPE: Journal
LANGUAGE: English

L4 ANSWER 43 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
TI Monoclonal antibody affinity **purification** of plasma proteins
removes viral contaminants
AB Monoclate is a highly purified Factor VIII prepared by a two column affinity
purification process. The procedure employs a monoclonal anti-von Willebrand
antibody to purify the **Factor VIII-von**
Willebrand factor complex from the cryoppt.
and an aminohexyl affinity column to remove any leached murine IgG and
effect some addnl. purification. Studies with HIV, pseudorabies, sinus,
vesicular stomatitis, and vaccinia viruses demonstrated that the Monoclate
manufacturing process reduced each of these viruses by at least 5 logs and that
heating at 60° for 30 h resulted in an overall virus titer reduction of
more than 9 logs. Monoclate has proven to be an effective therapeutic
agent for the treatment of Hemophilia. Monoclate has the added virtue of
a lower virus burden and less alloantigens and other proteins. Monoclate
can be reconstituted in less than a minute, and because of its high
potency and small volume, it can be rapidly infused. The method of
monoclonal affinity purification used to prepare Monoclate may prove to be a
generic process for reducing the virus load of therapeutic protein preps.

ACCESSION NUMBER: 1989:619158 HCAPLUS
DOCUMENT NUMBER: 111:219158
TITLE: Monoclonal antibody affinity **purification** of
plasma proteins removes viral contaminants
AUTHOR(S): Hrinda, M. E.; Tarr, C.; Curry, W.; Newman, J.;
Schreiber, A. B.; D'Alisa, R.
CORPORATE SOURCE: Rorer Biotechnol. Inc., King of Prussia, PA, 19406,
USA
SOURCE: Colloque INSERM (1989), 175(Biotechnol. Proteines
Plasma), 413-17
CODEN: CINMDE; ISSN: 0768-3154
DOCUMENT TYPE: Journal
LANGUAGE: English

L4 ANSWER 44 OF 44 HCAPLUS COPYRIGHT 2004 ACS on STN
TI **Purification** of factor VIII by monoclonal antibody affinity
chromatography
AB Monoclonal antibodies were raised to von Willebrand factor, and linked to
a solid-phase agarose support. Due to the high affinity of these
antibodies for the von Willebrand factor end of the **factor**
VIII/von Willebrand factor
complex, it was possible to effectively pull out the
factor VIII/von Willebrand
factor complex from com. concs. or cryoppts. The next
stage of the process involved eluting the factor VIII portion of the
complex from the von Willebrand factor. CaCl₂ at a concentration of
.apprx.0.25-0.3M was used to elute factor VIII, leaving the von Willebrand
factor bound to the monoclonal antibody column. Following concentration by
ultrafiltration, trace contaminants, such as von Willebrand factor,
fibrinogen, or fibronectin, could be removed by monoclonal antibodies
specific for them. Finally, the product was rechromatographed to allow
for further purification and concentration. The resultant factor VIII
preparation had a
concentration in the range 134-1172 units (U)/mL and a specific activity of
>2240

U/mg. A refined procedure and some applications are discussed.

ACCESSION NUMBER: 1988:434300 HCAPLUS
DOCUMENT NUMBER: 109:34300
TITLE: **Purification** of factor VIII by monoclonal
antibody affinity chromatography
AUTHOR(S): Zimmerman, Theodore S.
CORPORATE SOURCE: Scripps Clinic Res. Found., La Jolla, CA, 92037, USA
SOURCE: Seminars in Hematology (1988), 25(2, Suppl. 1), 25-6
CODEN: SEHEA3; ISSN: 0037-1963
DOCUMENT TYPE: Journal
LANGUAGE: English

Refine Search

Search Results -

Terms	Documents
6228613.pn.	1

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L13

Search History

DATE: Friday, May 21, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=OR

<u>L13</u>	6228613.pn.	1	<u>L13</u>
<u>L12</u>	6307032.pn.	1	<u>L12</u>
<u>L11</u>	19 and high molecular weight vWF multimer	1132985	<u>L11</u>
<u>L10</u>	11 and L9	0	<u>L10</u>
<u>L9</u>	12 and L8	143	<u>L9</u>
<u>L8</u>	14 and L7	143	<u>L8</u>
<u>L7</u>	15 and L6	93994	<u>L7</u>
<u>L6</u>	factor VIII-von Willebrand factor complex	971739	<u>L6</u>
<u>L5</u>	purification and l3	104349	<u>L5</u>
<u>L4</u>	12 and L3	674	<u>L4</u>
<u>L3</u>	factor VIII same2 von Willebrand factor complex	1055539	<u>L3</u>
<u>L2</u>	Zhou.in.	1221	<u>L2</u>
<u>L1</u>	6605222.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Refine Search

Search Results -

Terms	Documents
5679776.pn.	1

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L14

Refine Search

Recall Text

Clear

Interrupt

Search History

 DATE: Friday, May 21, 2004 [Printable Copy](#) [Create Case](#)

 Set Name Query
 side by side

 Hit Count Set Name
 result set

DB=USPT; PLUR=YES; OP=OR

<u>L14</u>	5679776.pn.	1	<u>L14</u>
<u>L13</u>	6228613.pn.	1	<u>L13</u>
<u>L12</u>	6307032.pn.	1	<u>L12</u>
<u>L11</u>	19 and high molecular weight vWF multimer	1132985	<u>L11</u>
<u>L10</u>	11 and L9	0	<u>L10</u>
<u>L9</u>	12 and L8	143	<u>L9</u>
<u>L8</u>	14 and L7	143	<u>L8</u>
<u>L7</u>	15 and L6	93994	<u>L7</u>
<u>L6</u>	factor VIII-von Willebrand factor complex	971739	<u>L6</u>
<u>L5</u>	purification and I3	104349	<u>L5</u>
<u>L4</u>	12 and L3	674	<u>L4</u>
<u>L3</u>	factor VIII same2 von Willebrand factor complex	1055539	<u>L3</u>
<u>L2</u>	Zhou.in.	1221	<u>L2</u>
<u>L1</u>	6605222.pn.	1	<u>L1</u>

END OF SEARCH HISTORY